Colgate-Palmolive Co. 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Colgate-Palmolive Co. for the period ended September 30, 1994. The company operates in Oral, Personal, and Household Care, as well as Specialty Marketing segments. The report covers the third quarter and the first nine months of 1994, comparing results to the same periods in 1993.
Key Financial Metrics
| Metric (in Millions) | Q3 1994 | Q3 1993 | 9 Months 1994 | 9 Months 1993 |
|---|---|---|---|---|
| Net Sales | $1,930.7 | $1,823.1 | $5,591.8 | $5,300.9 |
| Gross Profit | $951.8 | $870.1 | $2,716.6 | $2,536.1 |
| Gross Margin | 49.3% | 47.7% | 48.6% | 47.8% |
| Net Income | $151.0 | $142.8 | $443.1 | $67.8* |
| Diluted EPS | $0.93 | $0.82 | $2.72 | $0.35* |
| Operating Cash Flow (9mo) | $528.2 (vs $488.2 prior year) | |||
| Cash & Equivalents | $180.9 (Sep 30, 1994) | |||
| Total Debt | $2,009.1 (Notes/Loans + Current LT + LT Debt) |
*1993 nine-month net income and EPS were significantly impacted by a one-time cumulative effect of accounting changes totaling $358.2 million.
Material Changes vs. Prior Period
- Sales Growth: Worldwide sales increased 6% in Q3 and 6% for the nine-month period. Excluding divestitures, unit volume grew 6% in Q3 and 7% year-to-date.
- Regional Performance: Strong growth in Latin America (+15% Q3), Asia/Africa (+14% Q3), and Europe (+12% Q3) offset a 10% sales decline in North America due to retailer inventory reductions.
- Profitability: Gross margins improved across all regions. EBIT increased 13% in Q3 and 7.8% for the nine-month period.
- Expenses: Selling, general, and administrative (SG&A) expenses rose as a percentage of sales (36.1% in Q3 vs 35.3% in 1993) primarily due to increased advertising spending.
- Interest Costs: Net interest expense more than doubled in Q3 ($26.4M vs $12.6M) due to increased debt levels associated with the share repurchase program.
Guidance, Outlook, and Risks
- Share Repurchases: The company continues an aggressive share repurchase program to optimize capital structure. Approximately 5 million shares were repurchased for $294.5 million through September 30, 1994.
- Divestitures: Results for the Specialty Marketing segment were impacted by the divestiture of Princess House and Hill's veterinary drug distribution business. A one-time after-tax charge of $5.2 million related to the Princess House sale was recorded in 1994.
- Liquidity: Working capital increased to $787.8 million. The company maintains a $750 million credit facility and has filed a shelf registration for $500 million in debt securities.
- Accounting Changes: The company adopted SFAS No. 115 effective January 1, 1994, with no material impact on results. The 1993 results included a significant charge for the adoption of SFAS No. 106, 109, and 112.
Investor Verification Checklist
- North America Inventory: Verify the extent of retailer inventory destocking in the US and its expected duration, as this caused a 10% sales decline in the region.
- Debt Servicing: Confirm the sustainability of the increased interest expense ($62.8M for 9 months) relative to operating cash flow ($528.2M) given the aggressive debt-funded buyback strategy.
- Divestiture Impact: Assess the long-term strategic impact of the Princess House and Hill's veterinary drug divestitures on the Specialty Marketing segment's future growth.
- Advertising ROI: Evaluate the return on the increased advertising spend, which drove SG&A higher as a percentage of sales.
- Foreign Exchange: Review the specific impact of currency fluctuations on the reported growth in Europe and Asia/Africa regions.